Diabetes Educators: Understanding the Role of Finerenone in Chronic Kidney Disease Associated with Type 2 Diabetes Mellitus
Authors:
- Anne M. KoméAKAnne M. Komé
- Anita YangAYAnita Yang
- Patrick GeePGPatrick Gee
- Klara R. KleinKKKlara R. Klein
Open Access
- 4 March 2025
- journal article
- editorial
- Published by Springer Nature in Diabetes Therapy
- Vol. 16 (5) , 763-784
Abstract
People living with type 2 diabetes mellitus (T2DM) are at risk of developing diabetes-related complications such as chronic kidney disease (CKD). Screening for CKD is considered the standard of diabetes care, but less than half of people living with diabetes in the United States receive guideline-directed kidney disease testing. Despite recent pharmacologic advances for the treatment of this condition, insufficient screening delays both diagnosis and treatment of diabetes-related CKD and increases the risk of poor outcomes. The nonsteroidal mineralocorticoid receptor antagonist finerenone is an orally administered drug that, when taken with the maximum tolerated dose of a renin–angiotensin–aldosterone system inhibitor, can provide kidney and cardiovascular benefits for people living with T2DM-related CKD. Yet, uptake of this drug has been slow. Increasing awareness of finerenone may encourage its use in clinical practice. Diabetes educators are healthcare professionals (HCPs) with extensive diabetes care experience who encourage diabetes self-management and provide patients with education on the prevention of diabetes-related complications. Diabetes educators bridge knowledge and care gaps among other HCPs by facilitating communication between members of the care team and raising awareness on the importance of CKD prevention and screening. Additionally, diabetes educators reinforce the clinical evidence behind available treatments to promote adherence to guidelines. Here, the evidence for finerenone in T2DM-related CKD and the role of the diabetes educator from both patient and HCP perspectives are reviewed. Graphical abstract available for this article. Graphical AbstractKeywords
Funding Information
- Bayer Corporation
This publication has 33 references indexed in Scilit:
- Finerenone in heart failure and chronic kidney disease with type 2 diabetes: FINE-HEART pooled analysis of cardiovascular, kidney and mortality outcomesNature Medicine, 2024
- Baseline Characteristics of Patients with Heart Failure with Mildly Reduced or Preserved Ejection Fraction: The FINEARTS-HF TrialEuropean Journal of Heart Failure, 2024
- Optimizing Multidisciplinary Care of Patients with Chronic Kidney Disease and Type 2 Diabetes MellitusDiabetes Therapy, 2023
- Medicated-related burden and adherence in patients with co-morbid type 2 diabetes mellitus and hypertensionHeliyon, 2023
- KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney DiseaseKidney International, 2022
- American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan—2022 UpdateEndocrine Practice, 2022
- A Narrative Review of Diabetic Kidney Disease: Previous and Current Evidence-Based Therapeutic ApproachesAdvances in Therapy, 2022
- AWAREness of Diagnosis and Treatment of Chronic Kidney Disease in Adults With Type 2 Diabetes (AWARE-CKD in T2D)Canadian Journal of Diabetes, 2022
- Drug-Induced HyperkalemiaDrug Safety, 2014
- Chapter 3: Management of progression and complications of CKDKidney International Supplements, 2013